Recent News

• 03.30.2026 - Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate
• 03.26.2026 - Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan
• 03.25.2026 - Medicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate Update
• 03.18.2026 - Medicus Pharma To Discuss Positive Skinject® Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst
• 03.18.2026 - Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst
• 03.16.2026 - Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26
• 03.10.2026 - Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum
• 03.09.2026 - Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset

Recent Filings

• 03.27.2026 - EFFECT Notice of Effectiveness
• 03.27.2026 - EFFECT Notice of Effectiveness
• 03.27.2026 - EFFECT Notice of Effectiveness
• 03.25.2026 - 424B3 Prospectus [Rule 424(b)(3)]
• 03.25.2026 - POS AM Post-Effective amendments for registration statement
• 03.25.2026 - POS AM Post-Effective amendments for registration statement
• 03.25.2026 - 424B3 Prospectus [Rule 424(b)(3)]
• 03.25.2026 - 424B3 Prospectus [Rule 424(b)(3)]
• 03.25.2026 - 424B3 Prospectus [Rule 424(b)(3)]
• 03.25.2026 - POS AM Post-Effective amendments for registration statement